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Abstract
Background: The polymorphism 5,10-methylenetetrahydrofolate reductase (MTHFR) c.1298A>C is associated with
various diseases. 45 DNA samples homozygous for the A allele and 40 DNA probes homozygous for the C allele
were taken from healthy German subjects of white Caucasian origin to analyze the haplotype of the two MTHFR
c.1298A>C alleles. Samples were genotyped for the polymorphism MTHFR c.677C>T and for the silent
polymorphisms MTHFR c.129C>T, IVS2 533 G>A, c.1068C>T and IVS10 262C>G.
Findings: Haplotype construction revealed that the C-allele of MTHFR c.1298A>C was more frequently observed in
cis with c.129T, IVS2 533A, c.677C, c.1068T, and IVS10 262 G than expected from normal distribution. Estimation of
the most recent common ancestor with the DMLE + 2.3 program resulted in an estimated age of approximately
36,660 years of the MTHFR c.1298C allele.
Conclusion: Given that the era from 30,000 to 40,000 years ago is characterised by the spread of modern humans
in Europe and that the prevalence of the MTHFR c.1298C allele is significantly higher in Central Europe in
comparison to African populations, a selective advantage of MTHFR c.1298C could be assumed, e. g. by adaption
to changes in the nutritional environment. The known founder ancestry of the T allele of MTHFR c.677C>T allele,
together with the present data suggests that the MTHFR mutant alleles c.677T and 1298C arose from two
independent ancestral alleles, that both confer a selective advantage.
Background
The monomeric enzyme 5,10-methylenetetrahydrofolate
reductase (MTHFR, EC 607093, OMIM 236250) catalyzes
the reduction of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate (5-MTHF). 5-MTHF is a methyl
group donor for the remethylation of homocysteine to
methionine. The T-allele of the MTHFR polymorphism
c.677C>T (A222V, rs1801133) is associated with reduced
MTHFR activity and, thus with an increased total plasma
homocysteine level [1]. The frequency of the T-allele of
MTHFR c.677C>T differs between ethnic groups and
ranges from 6-10% in African countries [2,3] to more than
17% in Caucasians in North America [1,4,5] and more
than 50% in Mexican populations [3]. In the literature,
the presence of the T-allele has been associated with
cardiovascular and cerebrovascular diseases, venous
thrombosis, neural tube defects and various cancers [6]. It
was hypothesized that this might be due to increased
plasma homocysteine levels in carriers of the MTHFR
c.677T allele [7]. In addition, the allele’s function for DNA
synthesis and methylation could be an important factor
for the development of such diseases [8]. Previously, we
demonstrated that the polymorphism MTHFR c.677C>T
(A222V, rs1801133) is associated with a defined MTHFR
haplotype in the German population suggesting a founder
effect [9]. This result could be confirmed by other groups
for other populations [10].
In the present study, we investigated the second func-
tionally relevant MTHFR SNP, the c.1298A>C (E429A,
rs1801131) [11]. The derived C-allele of MTHFR
c.1298A>C has been found to be associated with
decreased MTHFR activity in lymphocytes and cultured
human fibroblasts, although this effect was smaller than
the effect shown for the T-allele of MTHFR c.677C>T
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[11-13]. However, the C-allele of the MTHFR
c.1298A>C polymorphism could be linked to later onset
of neurodegenerative diseases and a lower risk for differ-
ent types of cancer [12,14]; [15-18]. Here, we report
haplotype data on the c.1298A>C polymorphism in a
healthy German population selected by the c.1298A>C
genotype suggesting a founder allele in the late ancestry.
Methods
The MTHFR c.1298A>C polymorphism (rs 1801131) was
studied in samples of genomic DNA prepared from per-
ipheral leukocytes of 500 healthy controls recruited for
previous studies [19,20]. All individuals were Caucasians
from Germany living in the area of Bonn. The distribution
of AA/AC/CC was 260/200/40 or 0.52/0.40/0.08, respec-
tively, which was in line with the Hardy-Weinberg-Equili-
brium. Out of 500 DNA samples, we selected 40 samples
that were homozygous for the C allele and 45 samples
demonstrating homozygosity for the A-allele. All samples
were genotyped for the missense polymorphism MTHFR
c.677C>T (rs 1801133) and for the silent polymorphisms
MTHFR c.129C>T (rs 2066462), IVS2 533 G>A (poly-
morphism at nucleotide number 533 in intron 2 [21]),
c.1068C>T (rs 2066462) and IVS10 262C>G (polymorph-
ism at nucleotide number 262 in intron 10 [21,22]. Haplo-
types were constructed from genotypes using the
maximum likelihood method (Software HAPMAX, devel-
oped by M. Krawczak, http://www.uni-kiel.de/medinfo/
mitarbeiter/krawczak/download/) and analysed with a c2
test (one degree of freedom). Estimation of the most
recent common ancestor of the derived allele of MTHFR
c.1298C was performed by means of the DMLE + 2.3 pro-
gram http://www.dmle.org[23]. The chromosome map dis-
tance of the polymorphisms was calculated from the
pubmed SNP database http://www.ncbi.nlm.nih.gov/SNP/
snp_ref.cgi?locusId=4524 (Table 1). The population
growth rate in Germany was set to 0.0075 [24], the current
German population to 82,200,000 (Population Reference
Bureau. 2008 World Population Data Sheet) and the mean
allele frequency of the MTHFR c.1298C allele to 28%
according to the results from the present study derived
from 500 samples which was in line with results from
other German populations [14,20,25,26]. The generation
length was defined as 20 years.
The study was approved by the local ethical commit-
tee of the University Bonn, Germany, and all individuals
gave written informed consent.
Results
Selection of DNA samples was based on their MTHFR
c.1298A>C genotype. Therefore, we only performed hap-
lotype analysis stratified for this genotype and not for the
other MTHFR SNPs since representative distribution of
these SNPs in our sample could not be assumed. HAP-
MAX analysis revealed a linkage disequilibrium of
MTHFR c.1298A>C to the other SNPs. The C-allele of
MTHFR c.1298A>C was more often observed in cis with
c.129T; IVS2 533A; c.677C; c.1068T; IVS10 262 G than
expected from a normal distribution referring to the hap-
lotype data obtained for the wildtype A-allele (Table 2).
Accordingly, automated haplotype construction revealed
different haplotypes of maximum likelihood for c.1298A
and c.1298C (Table 3). Estimation of the most recent
common ancestor of the MTHFR c.1298A>C alleles with
the help of the DMLE + 2.3 software showed a major
peak of the posterior distribution of 1833 generations
(95% credible set, 1678-2176 generations) (Figure 1).
Given a generation length of 20 years, this finding trans-
lates in an age of approximately 36,600 years (33560-
435200).
Table 1 Chromosome map distances
SNP Contig position NT_021937 Distance in bp to c.129C>T
c.129C>T 6.400.338 0
IVS2 533 G>A 6.398.006 2.332
c.677C>T 6.393.745 6.593
c.1068C>T 6.392.263 8.076
c.1298A>C 6.391.843 8.495
IVS10 262C>G 6.388.372 11.966
Table 2 Relative frequency of polymorphisms of A- and C-alleles of MTHFR c.1298A>C, Pearson’s Chi-Square Test.
c.129C>T IVS2 533 G>A c.677C>T c.1068C>T IVS10 262C>G
C T Chi2;
p
G A Chi2;
p
C T Chi2;
p
C T Chi2;
p
C G Chi2;
p
1298 A 0.99 0.01 15.92 0.84 0.16 19.81 0.49 0.51 52.63 0.99 0.01 15.92 0.70 0.30 30.53
1298 C 0.81 0.19 < 0.001 0.52 0.48 < 0,001 0.99 0.01 < 0.001 0.81 0.19 < 0.001 0.28 0.72 < 0,01
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Table 3 Haplotypes of A- and C-alleles of MTHFR c.1298A>C.
HT c.129C>T IVS2 533 G>A c.677C>T c.1068C>T IVS10 262C>G 1298A 1298C
1 C G C C C 0.3201 0.1043
2 C G T C C 0.2956 0
3 C G T C G 0.1113 0
4 C G C C G 0.1026 0.2287
5 C A T C C 0.0661 0
6 C A C C G 0.0432 0.3468
7 C A T C G 0.0384 0
8 T A C C C 0.0114 0.1279
9 C G C T C 0.0114 0.1128
10 T G C T C 0 0.0390
11 T A C T C 0 0.0160
12 T G C T C 0 0.0122
13 C G T T C 0 0.0122
Haplotypes with an estimated frequency below 0.01 are not shown. Numbering refers to haplotypes of c.1298A alleles (1-13; the additional c.1298 haplotypes not
observed in c.1298A (C) alleles were numbered consecutively regarding their frequency). Frequencies are shown as the ratio of total amount of each 1298A and
1298C-alleles.
Figure 1 Estimation of the most recent common ancestor of MTHFR c.1298C with the DMLE + 2.3 program.
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Discussion
In our German population the A- and the C-allele of
MTHFR c.1298A>C demonstrated different haplotypes.
The most recent common ancestor of these alleles was
calculated with approximately 36,600 years. However, ana-
lysis of additional populations is required to definitely
determine the age of the ancestor allele.
The selection of samples for homozygosity was per-
formed to achieve an easier allocation of haplotypes to the
A versus C allele which would have been more difficult in
heterozygotes (AC) for MTHFR c.1298A>C. Due to this
biased selection, the observed frequencies of the other
MTHFR SNPs are not representative for a general popula-
tion. Nevertheless, this approach was feasible to approxi-
mate haplotype frequencies in A versus C alleles of
MTHFR c.1298A>C and to estimate the age of the derived
allele, c.1298C. Although the DMLE program predicted
the most likely age to be approximately 36,600 years
according to the major peak, our analysis revealed at least
one additional lower peak (Figure 1) that might be artifi-
cial or due to the presence of an undefined subpopulation
in our study cohort. This as well as the large confidence
interval of the estimated age requires replication of our
findings in additional samples and other populations.
Our age estimation of the most recent common ances-
tor of the studied alleles falls into a time period (30,000
to 40,000 years ago, the Aurignacian) which is typically
associated with the spread of modern humans (Homo
sapiens) in Europe [27,28]. The frequency of the MTHFR
c.1298C allele is significantly higher in central Europe in
comparison to African populations [3]. In addition, diet-
ary folate intake can profoundly modify the effect of the
C-allele on disease association, and the availability and
intake of folate is different in Europe and Africa [29]. In
summary, this could indicate an increased frequency of
the C-allele due to changes in the (nutritional) environ-
ment leading to selective advantages of the C-allele.
Presence of the C-allele has been associated with a
later onset of neurodegenerative diseases [12,14], better
fertility (however, only observed for in vitro fertilisation)
[30], rarer occurrence of chromosomal aberrations
(Down’s Syndrome [31]), and lower cancer risk [15-18].
However, adverse effects like an increased risk of neural
tube defects [11], hypertension [32] or acute myeloid
leukemia in Brazilian children [33] were also described.
Besides historical genetic aspects, the haplotypes pre-
sented in this study might be helpful for perinatal diag-
nosis of MTHFR deficiency based on haplotype analysis
in the case of an unknown MTHFR mutation (OMIM
236250). Furthermore, haplotypes might be used for loss
of heterozygosity studies comprising chromosome 1p36,
which is involved e.g. in glioblastoma formation [34]. In
addition, the known linkage disequilibrium of the two
MTHFR c.677T and c.1298C alleles [35,36] was recon-
firmed in our study.
Conclusion
The previously described founder effect for the c.677T
allele [9] supported by the present data suggests that the
MTHFR c.677T and c.1298C alleles arose from two
independent ancestral alleles, that both confer a selec-
tive advantage.
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